Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacoepidemiological Study of the Impact of Roactemra Treatment on Fatigue in Rheumatoid Arthritis Patients in a Real Life Setting

Next Previous
X
Search
Trial Profile

Pharmacoepidemiological Study of the Impact of Roactemra Treatment on Fatigue in Rheumatoid Arthritis Patients in a Real Life Setting

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms PEPS
  • Sponsors Roche

    • Most Recent Events

    • 17 Jun 2017 Results of pooled analysis (n=1494) of three observational studies (PEPS, Spare-1 and Act-solo), presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 07 Sep 2015 Results published in the Clinical and Experimental Rheumatology.
    • 16 Mar 2012 Actual number of patients changed from 387 to 719 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top